{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:51:39Z","timestamp":1791460299186,"version":"4.3.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03435-y","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:55:35Z","timestamp":1791453335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer-associated fibroblasts in therapeutic resistance of hepatocellular carcinoma: evidence, mechanisms, and translational implications"],"prefix":"10.1007","volume":"43","author":[{"given":"Tao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"3","key":"3435_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"3435_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"10126","key":"3435_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"10504","key":"3435_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","volume":"406","author":"SL Chan","year":"2025","unstructured":"Chan SL, et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet. 2025;406(10504):731\u201378.","journal-title":"Lancet"},{"key":"3435_CR5","doi-asserted-by":"crossref","unstructured":"Wang H et al. POSTN(+) cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma. J Immunother Cancer, 2024;12(7):e008721.","DOI":"10.1136\/jitc-2023-008721"},{"issue":"1","key":"3435_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s40425-019-0749-z","volume":"7","author":"BP Keenan","year":"2019","unstructured":"Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7(1):267.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"3435_CR7","doi-asserted-by":"publisher","first-page":"101170","DOI":"10.1016\/j.xcrm.2023.101170","volume":"4","author":"AM Roy","year":"2023","unstructured":"Roy AM, Iyer R, Chakraborty S. The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability. Cell Rep Med. 2023;4(9):101170.","journal-title":"Cell Rep Med"},{"issue":"5","key":"3435_CR8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773\u201396.","journal-title":"Hepatology"},{"key":"3435_CR9","doi-asserted-by":"crossref","unstructured":"Pan Y et al. Cancer-associated fibroblasts: multidimensional players in liver cancer. 2025. Volume 15\u20132025.","DOI":"10.3389\/fonc.2025.1454546"},{"issue":"7","key":"3435_CR10","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, et al. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55(7):1322\u201332.","journal-title":"Exp Mol Med"},{"issue":"4","key":"3435_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jcmgh.2023.01.006","volume":"15","author":"F Ying","year":"2023","unstructured":"Ying F, Chan MSM, Lee TKW. Cancer-associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma. Cell Mol Gastroenterol Hepatol. 2023;15(4):985\u201399.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"3435_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2016.05.022","volume":"379","author":"J Liu","year":"2016","unstructured":"Liu J, et al. Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-\u03b2 pathways. Cancer Lett. 2016;379(1):49\u201359.","journal-title":"Cancer Lett"},{"issue":"1","key":"3435_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159.","journal-title":"Mol Cancer"},{"issue":"5","key":"3435_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/cbin.12154","volume":"48","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunity. Cell Biol Int. 2024;48(5):577\u201393.","journal-title":"Cell Biol Int"},{"issue":"4","key":"3435_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41419-018-0458-4","volume":"9","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, et al. Cancer-associated fibroblasts induce PDL1\u2009+\u2009neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 2018;9(4):422.","journal-title":"Cell Death Dis"},{"issue":"2","key":"3435_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12072-025-10788-5","volume":"19","author":"Y Li","year":"2025","unstructured":"Li Y, Hamad M, Elkord E. Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets. Hepatol Int. 2025;19(2):325\u201336.","journal-title":"Hepatol Int"},{"key":"3435_CR17","doi-asserted-by":"publisher","first-page":"1620075","DOI":"10.3389\/fimmu.2025.1620075","volume":"16","author":"X Shi","year":"2025","unstructured":"Shi X, et al. Cancer-associated fibroblasts in hepatocellular carcinoma: origins, heterogeneity, and therapeutic implications. Front Immunol. 2025;16:1620075.","journal-title":"Front Immunol"},{"issue":"50","key":"3435_CR18","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3435_CR19","doi-asserted-by":"crossref","unstructured":"Nakamura D et al. Spatial and functional polarization of cancer-associated fibroblasts with CXCR4-mediated immune modulation in hepatocellular carcinoma. Hepatol Commun. 2026;10(4):e0930.","DOI":"10.1097\/HC9.0000000000000930"},{"issue":"1","key":"3435_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.iliver.2022.12.002","volume":"2","author":"H Chi","year":"2023","unstructured":"Chi H, et al. Single-cell transcriptome analysis reveals a cancer-associated fibroblast marker gene signature in hepatocellular carcinoma that predicts prognosis. Iliver. 2023;2(1):16\u201325.","journal-title":"Iliver"},{"issue":"1","key":"3435_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13073-024-01367-8","volume":"16","author":"SY Jing","year":"2024","unstructured":"Jing SY, et al. Spatial multiomics reveals a subpopulation of fibroblasts associated with cancer stemness in human hepatocellular carcinoma. Genome Med. 2024;16(1):98.","journal-title":"Genome Med"},{"issue":"1","key":"3435_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1186\/s12967-024-05613-w","volume":"22","author":"W Tong","year":"2024","unstructured":"Tong W, et al. Spatial transcriptomics reveals tumor-derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment. J Transl Med. 2024;22(1):840.","journal-title":"J Transl Med"},{"issue":"4","key":"3435_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cac2.12414","volume":"43","author":"JW Eun","year":"2023","unstructured":"Eun JW, et al. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun (Lond). 2023;43(4):455\u201379.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"3435_CR24","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78(4):770\u201382.","journal-title":"J Hepatol"},{"issue":"1","key":"3435_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40364-024-00622-9","volume":"12","author":"P Lyu","year":"2024","unstructured":"Lyu P, et al. Advances in targeting cancer-associated fibroblasts through single-cell spatial transcriptomic sequencing. Biomark Res. 2024;12(1):73.","journal-title":"Biomark Res"},{"key":"3435_CR26","doi-asserted-by":"crossref","unstructured":"Peiffer R et al. Cancer-associated fibroblast diversity shapes tumor metabolism in pancreatic cancer. Cancers (Basel), 2022;15(1):61.","DOI":"10.3390\/cancers15010061"},{"issue":"3","key":"3435_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579\u201396.","journal-title":"J Exp Med"},{"issue":"1","key":"3435_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"3435_CR29","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102\u201323.","journal-title":"Cancer Discov"},{"issue":"1","key":"3435_CR30","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1186\/s12885-023-11613-8","volume":"23","author":"J Zhao","year":"2023","unstructured":"Zhao J, et al. Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12\/FOLR1. BMC Cancer. 2023;23(1):1198.","journal-title":"BMC Cancer"},{"issue":"6","key":"3435_CR31","doi-asserted-by":"publisher","first-page":"101330","DOI":"10.1016\/j.gendis.2024.101330","volume":"11","author":"Y Dong","year":"2024","unstructured":"Dong Y, et al. Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1. Genes Dis. 2024;11(6):101330.","journal-title":"Genes Dis"},{"issue":"6","key":"3435_CR32","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s13402-024-01032-7","volume":"47","author":"P Zhang","year":"2024","unstructured":"Zhang P, et al. GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation. Cell Oncol (Dordr). 2024;47(6):2439\u201360.","journal-title":"Cell Oncol (Dordr)"},{"issue":"5","key":"3435_CR33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/carcin\/bgab019","volume":"42","author":"H Chu","year":"2021","unstructured":"Chu H, et al. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells. Carcinogenesis. 2021;42(5):753\u201361.","journal-title":"Carcinogenesis"},{"key":"3435_CR34","doi-asserted-by":"publisher","first-page":"123599","DOI":"10.1016\/j.biomaterials.2025.123599","volume":"325","author":"L Zhu","year":"2026","unstructured":"Zhu L, et al. Cancer-associated fibroblasts regulating nanomedicine to overcome sorafenib resistance in hepatocellular carcinoma with portal vein tumor thrombus. Biomaterials. 2026;325:123599.","journal-title":"Biomaterials"},{"issue":"6","key":"3435_CR35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/ijc.2910560611","volume":"56","author":"D Tavian","year":"1994","unstructured":"Tavian D, et al. RT-PCR detection of fibronectin EDA\u2009+\u2009and EDB+ mRNA isoforms: molecular markers for hepatocellular carcinoma. Int J Cancer. 1994;56(6):820\u20135.","journal-title":"Int J Cancer"},{"issue":"5","key":"3435_CR36","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0168-8278(97)80322-4","volume":"27","author":"S Matsui","year":"1997","unstructured":"Matsui S, et al. Expression, localization and alternative splicing pattern of fibronectin messenger RNA in fibrotic human liver and hepatocellular carcinoma. J Hepatol. 1997;27(5):843\u201353.","journal-title":"J Hepatol"},{"issue":"3","key":"3435_CR37","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1189\/jlb.1206730","volume":"82","author":"SP Gondokaryono","year":"2007","unstructured":"Gondokaryono SP, et al. The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol. 2007;82(3):657\u201365.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"3435_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s13577-022-00800-7","volume":"36","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Pan Q, Shao Z. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib. Hum Cell. 2023;36(1):296\u2013311.","journal-title":"Hum Cell"},{"key":"3435_CR39","doi-asserted-by":"publisher","first-page":"111378","DOI":"10.1016\/j.cellsig.2024.111378","volume":"124","author":"KJ Lv","year":"2024","unstructured":"Lv KJ, et al. Cancer-associated fibroblasts promote the progression and chemoresistance of HCC by inducing IGF-1. Cell Signal. 2024;124:111378.","journal-title":"Cell Signal"},{"issue":"8","key":"3435_CR40","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/mc.23416","volume":"61","author":"W Qin","year":"2022","unstructured":"Qin W, et al. CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib. Mol Carcinog. 2022;61(8):764\u201375.","journal-title":"Mol Carcinog"},{"key":"3435_CR41","doi-asserted-by":"crossref","unstructured":"Xu W et al. FMO2(+) cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2025;13(5):e011648.","DOI":"10.1136\/jitc-2025-011648"},{"issue":"2","key":"3435_CR42","doi-asserted-by":"publisher","first-page":"e70117","DOI":"10.1002\/imt2.70117","volume":"5","author":"F Ji","year":"2026","unstructured":"Ji F, et al. Spatial multi-omics identifies a NOTCH3-mediated capillary-mCAF crosstalk driving immune exclusion in hepatocellular carcinoma. Imeta. 2026;5(2):e70117.","journal-title":"Imeta"},{"key":"3435_CR43","first-page":"0950","volume":"8","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, et al. POSTN(+) CAF-derived migrasomes drive hepatocellular carcinoma progression and confer resistance to immunotherapy. Res (Wash D C). 2025;8:0950.","journal-title":"Res (Wash D C)"},{"issue":"48","key":"3435_CR44","doi-asserted-by":"publisher","first-page":"e14661","DOI":"10.1002\/advs.202514661","volume":"12","author":"Y Li","year":"2025","unstructured":"Li Y, et al. Spatial Transcriptomics and snRNA-seq Expose CAF Niches Orchestrating Dual Stromal-Immune Barriers in Hepatocellular Carcinoma. Adv Sci (Weinh). 2025;12(48):e14661.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"3435_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","volume":"5","author":"Z Li","year":"2024","unstructured":"Li Z, et al. Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy. Nat Cancer. 2024;5(1):167\u201386.","journal-title":"Nat Cancer"},{"issue":"1","key":"3435_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, et al. Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma. Cell Discov. 2025;11(1):1.","journal-title":"Cell Discov"},{"issue":"14","key":"3435_CR47","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.7150\/ijbs.45446","volume":"16","author":"C Jia","year":"2020","unstructured":"Jia C, et al. Cancer-associated Fibroblasts induce epithelial-mesenchymal transition via the Transglutaminase 2-dependent IL-6\/IL6R\/STAT3 axis in Hepatocellular Carcinoma. Int J Biol Sci. 2020;16(14):2542\u201358.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"3435_CR48","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41419-022-04935-1","volume":"13","author":"H Xu","year":"2022","unstructured":"Xu H, et al. Cancer associated fibroblast-derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1\u03b1\/ZEB1 axis. Cell Death Dis. 2022;13(5):478.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3435_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-024-02106-8","volume":"23","author":"Z Lin","year":"2024","unstructured":"Lin Z, et al. Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications. Mol Cancer. 2024;23(1):191.","journal-title":"Mol Cancer"},{"key":"3435_CR50","doi-asserted-by":"publisher","first-page":"112282","DOI":"10.1016\/j.intimp.2024.112282","volume":"138","author":"H Shang","year":"2024","unstructured":"Shang H, et al. Exosomal circHIF1A derived from hypoxic-induced carcinoma-associated fibroblasts promotes hepatocellular carcinoma cell malignant phenotypes and immune escape. Int Immunopharmacol. 2024;138:112282.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3435_CR51","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/s12876-022-02594-2","volume":"22","author":"AL Jin","year":"2022","unstructured":"Jin AL, et al. Exosomal microRNAs in the DLK1-DIO3 imprinted region derived from cancer-associated fibroblasts promote progression of hepatocellular carcinoma by targeting hedgehog interacting protein. BMC Gastroenterol. 2022;22(1):505.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"3435_CR52","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12010-025-05404-z","volume":"198","author":"K Bai","year":"2026","unstructured":"Bai K, et al. Exosomal FOSL1 From Cancer-associated Fibroblasts Drives the Progression and Pro-tumorigenic M2 Macrophage Polarization of Hepatocellular Carcinoma By Activating PLAU Transcription. Appl Biochem Biotechnol. 2026;198(2):822\u201342.","journal-title":"Appl Biochem Biotechnol"},{"key":"3435_CR53","doi-asserted-by":"crossref","unstructured":"Qi Y et al. CAF-Released Exosomal miR-20a-5p Facilitates HCC Progression via the LIMA1-Mediated \u03b2-Catenin Pathway. Cells. 2022;11(23):3857.","DOI":"10.3390\/cells11233857"},{"issue":"1","key":"3435_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12964-025-02369-8","volume":"23","author":"H Huang","year":"2025","unstructured":"Huang H, et al. Senescent fibroblasts secrete CTHRC1 to promote cancer stemness in hepatocellular carcinoma. Cell Commun Signal. 2025;23(1):379.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"3435_CR55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41392-024-01887-0","volume":"9","author":"H Peng","year":"2024","unstructured":"Peng H, et al. Semaphorin 3\u00a0C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression. Signal Transduct Target Ther. 2024;9(1):169.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"3435_CR56","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/cas.12891","volume":"107","author":"Z Firtina Karagonlar","year":"2016","unstructured":"Firtina Karagonlar Z, et al. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci. 2016;107(4):407\u201316.","journal-title":"Cancer Sci"},{"key":"3435_CR57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.matbio.2022.06.009","volume":"111","author":"P Duch","year":"2022","unstructured":"Duch P, et al. Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma. Matrix Biol. 2022;111:207\u201325.","journal-title":"Matrix Biol"},{"key":"3435_CR58","doi-asserted-by":"crossref","unstructured":"Han T, et al. Repurposed acarbose targets nidogen-1 to remodel the tumor stroma and suppress portal vein tumor thrombus in hepatocellular carcinoma. Research (Wash D C). 2026;9:1161.","DOI":"10.34133\/research.1161"},{"issue":"41","key":"3435_CR59","doi-asserted-by":"publisher","first-page":"e2404784","DOI":"10.1002\/adma.202404784","volume":"36","author":"P Schneider","year":"2024","unstructured":"Schneider P, et al. Multicompartment Polyion Complex Micelles Based on Triblock Polypept(o)ides Mediate Efficient siRNA Delivery to Cancer-Associated Fibroblasts for Antistromal Therapy of Hepatocellular Carcinoma. Adv Mater. 2024;36(41):e2404784.","journal-title":"Adv Mater"},{"issue":"21","key":"3435_CR60","doi-asserted-by":"publisher","first-page":"e10006","DOI":"10.1002\/advs.202510006","volume":"13","author":"P Schneider","year":"2026","unstructured":"Schneider P, et al. Biodegradable carbonate nanogels loaded with anti mfap-5 sirna for anti-stromal therapy of hepatocellular carcinoma. Adv Sci (Weinh). 2026;13(21):e10006.","journal-title":"Adv Sci (Weinh)"},{"key":"3435_CR61","doi-asserted-by":"publisher","first-page":"113783","DOI":"10.1016\/j.jconrel.2025.113783","volume":"383","author":"X Yin","year":"2025","unstructured":"Yin X, et al. Nanoparticle-mediated dual targeting of stromal and immune components to overcome fibrotic and immunosuppressive barriers in hepatocellular carcinoma. J Control Release. 2025;383:113783.","journal-title":"J Control Release"},{"key":"3435_CR62","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jconrel.2025.01.066","volume":"379","author":"SL Cheng","year":"2025","unstructured":"Cheng SL, et al. CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinoma. J Control Release. 2025;379:967\u201381.","journal-title":"J Control Release"},{"issue":"25","key":"3435_CR63","doi-asserted-by":"publisher","first-page":"34932","DOI":"10.1021\/acsami.6c05969","volume":"18","author":"L Xiang","year":"2026","unstructured":"Xiang L, et al. FAP-\u03b1-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. ACS Appl Mater Interfaces. 2026;18(25):34932\u201351.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"3435_CR64","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12967-025-06192-0","volume":"23","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Integration of single-cell and spatial transcriptomics reveals fibroblast subtypes in hepatocellular carcinoma: spatial distribution, differentiation trajectories, and therapeutic potential. J Transl Med. 2025;23(1):198.","journal-title":"J Transl Med"},{"issue":"9","key":"3435_CR65","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1016\/j.acra.2025.04.016","volume":"32","author":"TC Wang","year":"2025","unstructured":"Wang TC, et al. High Fibroblast Activation Protein Expression in Hepatocellular Carcinoma: CT Imaging Features and Histological Characteristics. Acad Radiol. 2025;32(9):5137\u201349.","journal-title":"Acad Radiol"},{"issue":"11","key":"3435_CR66","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-024-07195-3","volume":"15","author":"G Fan","year":"2024","unstructured":"Fan G, et al. DKK1\u2009+\u2009tumor cells inhibited the infiltration of CCL19\u2009+\u2009fibroblasts and plasma cells contributing to worse immunotherapy response in hepatocellular carcinoma. Cell Death Dis. 2024;15(11):797.","journal-title":"Cell Death Dis"},{"issue":"9","key":"3435_CR67","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","volume":"2","author":"WJ Ho","year":"2021","unstructured":"Ho WJ, et al. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer. 2021;2(9):891\u2013903.","journal-title":"Nat Cancer"},{"key":"3435_CR68","doi-asserted-by":"publisher","first-page":"892250","DOI":"10.3389\/fimmu.2022.892250","volume":"13","author":"H Mi","year":"2022","unstructured":"Mi H, et al. Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma. Front Immunol. 2022;13:892250.","journal-title":"Front Immunol"},{"issue":"1","key":"3435_CR69","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13073-023-01218-y","volume":"15","author":"S Zhang","year":"2023","unstructured":"Zhang S, et al. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Genome Med. 2023;15(1):72.","journal-title":"Genome Med"},{"key":"3435_CR70","doi-asserted-by":"crossref","unstructured":"Chen Y et al. A Stromal-centered single-cell landscape identifies postn(+) fibroblasts as a high-risk stromal subset in hepatocellular carcinoma. Biomarkers. 2026:1\u201317.","DOI":"10.1080\/1354750X.2026.2678877"},{"issue":"5","key":"3435_CR71","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.ccell.2025.03.004","volume":"43","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer Cell. 2025;43(5):905\u2013e9246.","journal-title":"Cancer Cell"},{"issue":"6","key":"3435_CR72","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719\u201334.","journal-title":"Cancer Cell"},{"key":"3435_CR73","doi-asserted-by":"crossref","unstructured":"Qu, Y.A., et al., Understanding the Cancer-Associated Fibroblast (CAF) and Its Biomarker Fibroblast Activation Protein (FAP), and Aspects in Human Liver Cancer. Front Biosci (Landmark Ed), 2025. 30(12): p. 44837.","DOI":"10.31083\/FBL44837"},{"key":"3435_CR74","doi-asserted-by":"crossref","unstructured":"Li, H., et al., [18F]AlF-ND-bisFAPI PET imaging of fibroblast activation protein as a biomarker to monitor the progression of liver fibrosis. Hepatol Commun, 2024. 8(4): p. e0407.","DOI":"10.1097\/HC9.0000000000000407"},{"issue":"6","key":"3435_CR75","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00259-026-07804-7","volume":"53","author":"C Wang","year":"2026","unstructured":"Wang C, et al. Assessment of liver fibrosis and tumor burden in hepatocellular carcinoma using [(18)F]AlF-NOTA-FAPI-04 PET\/CT: a prospective study. Eur J Nucl Med Mol Imaging. 2026;53(6):3877\u201390.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3435_CR76","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1084\/jem.20122344","volume":"210","author":"EW Roberts","year":"2013","unstructured":"Roberts EW, et al. Depletion of stromal cells expressing fibroblast activation protein-\u03b1 from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013;210(6):1137\u201351.","journal-title":"J Exp Med"},{"issue":"6","key":"3435_CR77","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210(6):1125\u201335.","journal-title":"J Exp Med"},{"issue":"1","key":"3435_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-024-01099-2","volume":"32","author":"Z Cao","year":"2025","unstructured":"Cao Z, et al. Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects. J Biomed Sci. 2025;32(1):7.","journal-title":"J Biomed Sci"},{"issue":"3","key":"3435_CR79","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/cas.16443","volume":"116","author":"M Yamazaki","year":"2025","unstructured":"Yamazaki M, Ishimoto T. Targeting Cancer-associated fibroblasts: eliminate or reprogram? Cancer Sci. 2025;116(3):613\u201321.","journal-title":"Cancer Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03435-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03435-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03435-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:02:39Z","timestamp":1791457359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03435-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":79,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3435"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03435-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"314"}}